2-<(dimethylamino)methyl>-3-methylfuran | 20863-54-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-<(dimethylamino)methyl>-3-methylfuran
• 英文别名: 2-dimethylaminomethyl-3-methylfuran；N,N,3-trimethyl-2-furanmethanamine；N,N-dimethyl-1-(3-methylfuran-2-yl)methanamine
• CAS: 20863-54-1
• 化学式: C₈H₁₃NO
• 分子量: 139.197
• InChiKey: YHHPQMAEWZGPRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  16.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  sodium sulfate 、 2-<(dimethylamino)methyl>-3-methylfuran 在 正丁基锂 、 paraformaldehyde 作用下， 以 四氢呋喃 、 正己烷 、 水 、 乙酸乙酯 为溶剂， 生成 5-(dimethylaminomethyl)-4-methyl-2-furanmethanol
  参考文献：
  名称：

  Substituted furan compounds and pharmaceutical compositions containing

  摘要：

  该发明涉及一般公式##STR1##的化合物，以及其生理上可接受的盐和N-氧化物、水合物和生物前体，其中R.sub.1和R.sub.2可以相同也可以不同，每个代表氢、C.sub.1-8烷基、C.sub.4-8环烷基、C.sub.3-6烯基、含有1至4个碳原子的烷基残基的芳基烷基或被氧原子或基团##STR2##打断的C.sub.1-8烷基，其中R.sub.5代表氢或C.sub.1-8烷基，或者R.sub.1和R.sub.2可以与它们连接的氮原子一起形成饱和的单环5到7成员杂环环，还可以额外含有杂原子O或##STR3##，R.sub.3代表直链或支链C.sub.1-8烷基、在每个烷基残基中含有1至8个碳原子的烷氧烷基、C.sub.1-8羟基烷基、C.sub.1-8烷氧羰基、在每个烷基残基中含有1至8个碳原子的烷基硫烷基、卤素或芳基；R.sub.4代表氢、C.sub.1-8烷基、C.sub.3-6烯基或在每个烷基残基中含有1至8个碳原子的烷氧烷基；X代表--O--或--S--；Y代表.dbd.S、.dbd.O、.dbd.NR.sub.6或.dbd.CHNO.sub.2，其中R.sub.6代表氢、硝基、氰基、C.sub.1-8烷基、芳基、C.sub.1-8烷基磺酰基或芳基磺酰基；m表示一个从2到4的整数；n表示一个整数，可以是1或2，或者当X为--S--时，n也可以为零。该发明还涉及生产这种化合物的过程，含有它们的药物组合物以及在其生产中使用的某些新颖中间体，即一般式##STR4##的胺和一般式##STR5##的醇。式(I)的化合物显示作为选择性组织胺H.sub.2-拮抗剂的药理活性。

  公开号：

  US04288443A1
• 作为产物：
  描述：

  2-<(dimethylamino)methyl>-3-methylene-2,3-dihydrofuran 在 正丁基锂 作用下， 以 乙醚 、 正己烷 为溶剂， 反应 0.5h， 以87%的产率得到2-<(dimethylamino)methyl>-3-methylfuran
  参考文献：
  名称：

  Rearrangement of dimethyl(furylmethyl)ammonium and dimethyl(thienylmethyl)ammonium N-methylides. Isolation and reaction of nonaromatic intermediates

  摘要：

  3-[(Dimethylamino)methyl]-2-methylene-2,3-dihydrofuran (5o) and 2-[(dimethylamino)methyl]-3-methylene-2,3-dihydrofuran (12o) and their thiophene analogues 5s and 12s were prepared in high yields by fluoride-ion induced desilylation of NN-dimethyl-N-[(trimethylsilyl)methyl](2-furylmethyl)ammonium (3o) and -(3-furylmethyl)ammonium iodides (10o) and their thienylmethyl analogues 3s and 10s. Compound 59 or 12s was successfully converted to 3-[(dimethylamino)methyl](2-thienylmethyl)lithium (23s) or 2-[(dimethyl-amino)methyl](3-thienylmethyl)lithium (26s), which reacted with aldehydes to give [(dimethylamino)-methyl)(2-hydroxyalkyl)thiophenes 259 or 27s, respectively.

  DOI：

  10.1021/jo00046a025

文献信息

• 2-Amido-4-phenylthiazole Derivatives, The Preparation And The Therapeutic Use Thereof
  申请人：CASELLAS Pierre

  公开号：US20070259847A1

  公开（公告）日：2007-11-08

  The disclosure relates to 2-amido-4-phenylthiazole derivatives of general formula (I) below: in which R 1 , R 2 , R 3 , Y, m, n, and p are as defined in the disclosure; as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic use thereof.

  该公开涉及通式（I）如下的2-酰胺-4-苯基噻唑衍生物：其中R1、R2、R3、Y、m、n和p如公开所定义；以及它们的异构体、盐和溶剂合物，包含它们的药物组合物以及其治疗用途。
• Chemical compounds
  申请人：Bristol-Myers Company

  公开号：US04380638A1

  公开（公告）日：1983-04-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组成式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环；m为0至2的整数；n为2至4的整数；Z为硫，氧或亚甲基；而A为可选取代的苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂噻二唑基，呋喃基，噻吩基或吡啶基环；以及其非毒性药学上可接受的盐，水合物，溶剂合物或N-氧化物是新的抗溃疡剂。公开了其中间体和制备方法。
• Substituted 1,2,5-thiadiazole derivatives
  申请人：Bristol-Myers Company

  公开号：US04380639A1

  公开（公告）日：1983-04-19

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  该专利涉及一种组成式为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环；m为0到2的整数；n为2到4的整数；Z为硫，氧或亚甲基；而A为可选的取代苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧杂二唑基，呋喃基，噻吩基或吡啶基；以及其非毒性医药上可接受的盐，水合物，溶剂合物或N-氧化物是新的抗溃疡剂。还公开了其中间体和制备方法。
• Thiadiazole histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04471122A1

  公开（公告）日：1984-09-11

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2; n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  该专利描述了一种新型抗溃疡药物，即公式为##STR1##的组织胺H.sub.2-拮抗剂，其中p为1或2；R.sup.1为羟基、氨基、取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环；m为0至2的整数；n为2至4的整数；Z为硫、氧或亚甲基；A为可选取代的苯基、咪唑基、噻唑基、异噻唑基、噁唑基、异噁唑基、三唑基、噻二唑基、氧杂二唑基、呋喃基、噻吩基或吡啶基环；以及其无毒的药学上可接受的盐、水合物、溶剂化合物或N-氧化物。还公开了其中间体和制备方法。
• Histamine H.sub.2 -antagonists
  申请人：Bristol-Myers Company

  公开号：US04510309A1

  公开（公告）日：1985-04-09

  Histamine H.sub.2 -antagonists of the formula ##STR1## wherein p is 1 or 2; R.sup.1 is hydroxy, amino, substituted amino or a 5- to 9-membered fully saturated nitrogen-containing heterocyclic ring attached via its nitrogen atom; m is an integer of from 0 to 2, n is an integer of from 2 to 4; Z is sulfur, oxygen or methylene; and A is an optionally substituted phenyl, imidazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, furyl, thienyl or pyridyl ring; and nontoxic pharmaceutically acceptable salts, hydrates, solvates or N-oxides thereof are novel anti-ulcer agents. Intermediates and processes for their preparation are disclosed.

  组成式为##STR1##的组胺H.sub.2-拮抗剂，其中p为1或2;R.sup.1为羟基，氨基，取代氨基或通过其氮原子连接的5-至9-成员完全饱和的含氮杂环环；m为0至2的整数，n为2至4的整数；Z为硫，氧或亚甲基；而A为可选取代的苯基，咪唑基，噻唑基，异噻唑基，噁唑基，异噁唑基，三唑基，噻二唑基，氧化二唑基，呋喃基，噻吩基或吡啶基；以及其非毒性药用可接受的盐，水合物，溶剂化合物或N-氧化物是新的抗溃疡剂。还公开了其中间体和制备过程。